ストックスクリーナーアプリを入手
4.39
4.77%
-0.22
アフターアワーズ：
4.60
0.21
+4.78%
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Two Sigma Investments LP - Defense World
Class Action ReminderNFLX, KPTI & MNKBronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Two Sigma Advisers LP Buys 45,400 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Millennium Management LLC Lowers Stock Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment By Investing.com - Investing.com Nigeria
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment - Investing.com Australia
Karyopharm to Present at the Jefferies Global Healthcare Conference - Kilgore News Herald
Karyopharm to Present at the Jefferies Global Healthcare Conference | KPTI Stock News - GuruFocus
Northern Trust Corp Acquires 54,061 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI Stock News - GuruFocus
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Jane Street Group LLC - Defense World
Karyopharm increases share reserve for equity plan - Investing.com India
Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment - TipRanks
Karyopharm increases share reserve for equity plan By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Sells 817,711 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Hepatic Impairment Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Novartis, ApoPharma, Indivior Inc., Boehringer Ingelheim, Ocera Therapeutics, Orient Europharma, Karyopharm - Barchart.com
Focus Partners Wealth Makes New Investment in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com India
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27% - simplywall.st
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet - simplywall.st
Karyopharm at RBC Capital Markets: Strategic Insights on XPOVIO and Pipeline - Investing.com Australia
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - Eastern Progress
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? - sharewise
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World
Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World
Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus
KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus
Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire
KPTI: RBC Capital Lowers Price Target while Maintaining Outperform Rating | KPTI Stock News - GuruFocus
RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada
KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus
KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus
Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus
KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus
Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):